Browse the corpus

Alpha-glucosidase inhibitors (AGIs) are therapeutic agents in managing type 2 diabetes. Acarbose and miglitol are FDA-approved and are prominent members of this drug class. AGIs are also prescribed for patients with impaired glucose tolerance, demonstrating their utility in delaying the onset of diabetes in this cohort. Notably, these inhibitors prove advantageous for individuals at heightened risk of hypoglycemia or lactic acidosis, making them viable alternatives for those unsuitable for conventional antidiabetic medications like sulfonylureas and metformin. This comprehensive activity provides healthcare professionals with a thorough exploration of AGIs, covering the indications, mechanism of action, pharmacokinetics, administration, dosing, contraindications, warnings, precautions, adverse effects, and monitoring. This knowledge facilitates effective diabetes management and the prevention of associated complications. Objectives: Identify patients who would benefit from α-glucosidase inhibitors based on their clinical characteristics and glycemic control goals. Implement appropriate dosing strategies and treatment regimens for α-glucosidase inhibitors based on individual patient factors and treatment goals. Apply comprehensive patient education regarding the use of α-glucosidase inhibitors, including medication instructions, potential adverse effects, and self-management strategies. Implement strategies with pharmacists and other healthcare team members to monitor and manage potential drug interactions, adverse effects, and treatment adjustments associated with α-glucosidase inhibitors. Access free multiple choice questions on this topic.

Unlike sulfonylureas, this group of drugs does not cause hypoglycemia. However, combination therapy with sulfonylureas or insulin poses the risk of hypoglycemia; in mild-to-moderate hypoglycemia cases, the patient should keep glucose (dextrose) with them. Disaccharides such as sucrose and polysaccharides (cane sugar) would not be suitable for reversing hypoglycemia in patients taking AGIs as the effects of the drug would impair their digestion and absorption.[21] Severe hypoglycemia may require the administration of either intravenous glucose infusion or glucagon injection.

Alpha-glucosidase inhibitors are effective in patients with type 2 diabetes in improving the metabolic profile and potentially reducing the risk of long-term complications of hyperglycemia. They may be used as monotherapy or in combination with other antihyperglycemic drugs and insulin. They do not correlate with any serious adverse effects. This makes them particularly useful for patients with renal, cardiorespiratory, or liver problems, as these patients have a higher risk of developing lactic acidosis and are not good candidates for metformin therapy. These drugs also do not cause hypoglycemia, making them a helpful substitute for sulfonylureas, which are associated with frequent occurrences of hypoglycemia. Patients should receive counsel to maintain an appropriate diet, as high levels of carbohydrates can worsen gastrointestinal side effects. If used with other antidiabetic drugs, the patient should quickly carry glucose to reverse hypoglycemia. Management of type 2 diabetes requires an interprofessional approach that includes physicians, advanced practice practitioners, specialists, nursing staff, and pharmacists; all healthcare team members should educate the patients regarding adverse effects and instruct them to maintain an appropriately healthy diet.[19][22]